Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
05:39am, Tuesday, 17'th Mar 2026
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene...
Pinnacle Silver and Gold discovers new polymetallic mineralization at El Potrero
05:13am, Tuesday, 17'th Mar 2026
Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:PSGCF, FRA:P9J) said it has discovered previously unknown silver-lead-zinc mineralization at its El Potrero...
Bank of America Corp DE Cuts Stock Position in Novo Nordisk A/S $NVO
03:38am, Tuesday, 17'th Mar 2026
Bank of America Corp DE trimmed its position in shares of Novo Nordisk A/S (NYSE: NVO) by 9.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SE
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks
09:00am, Monday, 16'th Mar 2026
The drama and uncertainty around Novo Nordisk and Hims and Hers Health might finally be ending.
Novo Nordisk A/S - share repurchase programme
05:56am, Monday, 16'th Mar 2026
Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun
Game Creek Capital LP Purchases New Position in Novo Nordisk A/S $NVO
03:50am, Saturday, 14'th Mar 2026
Game Creek Capital LP acquired a new stake in Novo Nordisk A/S (NYSE: NVO) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
3 Dirt-Cheap Stocks to Buy With $1,000 Right Now
06:05pm, Friday, 13'th Mar 2026
Investors are understandably fearful that Uber Technologies' profits are going to be under a growing degree of pressure. Insurer Progressive's outstanding 2025 results were too good to last.
Stock Market Today (LIVE): Adobe CEO Steps Down; Iran and Oil Turmoil Spells A Volatile Friday
08:49am, Friday, 13'th Mar 2026
Top insights from the latest market news from Friday, March 13, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
Novo Nordisk A/S $NVO Stock Position Decreased by Bank of Montreal Can
04:04am, Friday, 13'th Mar 2026
Bank of Montreal Can cut its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 57.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The
Royce Smaller-Companies Growth Fund FY 2025: What Worked
08:35pm, Thursday, 12'th Mar 2026
Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated s
Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:46pm, Thursday, 12'th Mar 2026
Novo Nordisk (NVO) closed the most recent trading day at $38.02, moving 2.09% from the previous trading session.
14 Ideal 'Safer' Dividend Buys From 70 Mid-March Graham Value All-Stars (GVAS)
02:35pm, Thursday, 12'th Mar 2026
Top ten large cap value (GASV) stocks are forecasted to deliver an average 38.12% net gain by mid-March 2027, with yields up to 13.03%. Analyst targets suggest the five lowest-priced, highest-yield GA
Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably
10:25am, Thursday, 12'th Mar 2026
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid reve
Does This Deal Make Novo Nordisk Stock a Buy?
10:15am, Thursday, 12'th Mar 2026
Not many things have gone right for Novo Nordisk recently, but this is one of them.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
10:00am, Thursday, 12'th Mar 2026
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to
